Results 81 to 90 of about 98,806 (295)

Ethnicity in systemic AL amyloidosis may impact risk stratification

Haematologica
Not available.
Jahanzaib Khwaja, Sriram Ravichandran, Oliver Cohen, Darren Foard, Ana Martinez – Naharro, Lucia Venneri, Carol Whelan, Philip N. Hawkins, Julian Gillmore, Helen J. Lachmann, Shameem Mahmood, Marianna Fontana, Ashutosh Wechalekar   +12 more
doaj   +1 more source

Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis

Haematologica, 2016
Patients with immunoglobulin light chain amyloidosis are at risk for both thrombotic and bleeding complications. While the hemostatic defects have been extensively studied, less is known about thrombotic complications in this disease.
Katherine M. Bever, Luke I. Masha, Fangui Sun, Lauren Stern, Andrea Havasi, John L. Berk, Vaishali Sanchorawala, David C. Seldin, J. Mark Sloan   +8 more
doaj   +1 more source

Impact of early intensive GDMT on LVEF recovery and ICD decision making in de novo HFrEF

ESC Heart Failure, EarlyView.
Abstract Aims Implantable cardioverter‐defibrillator (ICD) implantation is recommended in patients with heart failure with reduced ejection fraction (HFrEF) and left ventricular ejection fraction (LVEF) ≤ 35% after 3 months of optimized medical therapy (OMT).
Diogo Rosa Ferreira, Daniel Inácio Cazeiro, Joana Brito, Rafael Santos, Joana Rigueira, Doroteia Silva, Nuno Lousada, Fausto Pinto, Dulce Brito, João Agostinho   +9 more
wiley   +1 more source

Predicting Structural Consequences of Antibody Light Chain N-Glycosylation in AL Amyloidosis

Pharmaceuticals
Background/Objectives: Antibody light chains form amyloid fibrils that lead to progressive tissue damage in amyloid light chain (AL) amyloidosis. The properties of each patient’s unique light chain appear to determine its propensity to form amyloid.
Gareth J. Morgan, Zach Yung, Brian H. Spencer, Vaishali Sanchorawala, Tatiana Prokaeva   +4 more
doaj   +1 more source

Association of Cerebral Amyloidosis, Blood Pressure, and Neuronal Injury with Late-Life Onset Depression [PDF]

, 2016
Min Soo Byun, Young Min Choe, Bo Kyung Sohn, Dahyun Yi, Ji‐Young Han, Jinsick Park, Hyo Jung Choi, Hyewon Baek, Jun Ho Lee, Hyun Jung Kim, Yu Kyeong Kim, Eun Jin Yoon, Chul-Ho Sohn, Jong Inn Woo, Dong Young Lee   +14 more
openalex   +1 more source

Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities

ESC Heart Failure, Volume 12, Issue 2, Page 723-726, April 2025.
Stephan von Haehling
wiley   +1 more source

Exercise‐induced out‐of‐proportion increase in afterload and impaired right ventricular contractile reserve in HFpEF

ESC Heart Failure, EarlyView.
Non‐cardiac dyspnoea (n = 34, NCD) and heart failure with preserved ejection fraction (n = 34, HFpEF) patients were classified according to right heart catheterisation. Cardiovascular magnetic resonance derived right ventricular (RV) haemodynamic indices for afterload (Ea), contractility (Ees) and RV/pulmonary artery coupling (Ea/Ees) were evaluated ...
Jan Sebastian Wolter, Alexander Schulz, Torben Lange, Steffen D. Kriechbaum, Shelby Kutty, Johannes T. Kowallick, Julia M. Treiber, Andreas Rolf, Samuel Sossalla, Gerd Hasenfuß, Andreas Schuster, Sören J. Backhaus   +11 more
wiley   +1 more source

AA Amyloidosis and Atypical Familial Mediterranean Fever with Exon 2 and 3 Mutations [PDF]

, 2017
Junko Yabuuchi, Noriko Hayami, Junichi Hoshino, Keiichi Sumida, Tatsuya Suwabe, Toshiharu Ueno, Akinari Sekine, Masahiro Kawada, Masayuki Yamanouchi, Rikako Hiramatsu, Eiko Hasegawa, Naoki Sawa, Kenmei Takaichi, Takeshi Fujii, Kenichi Ohashi, Kiyoshi Migita, Takao Masaki, Yoshifumi Ubara   +17 more
openalex   +1 more source

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Real‐world effectiveness of targeted therapies in ATTR cardiomyopathy: A meta‐analysis integrating population‐based data

ESC Heart Failure, EarlyView.
Summary of the meta‐analysis evaluating the effectiveness of targeted therapies for transthyretin amyloid cardiomyopathy (ATTR‐CM). Pooled data from 10 studies (n = 5203) showed a 39% relative reduction in all‐cause mortality (RR: 0.61, 95% CI: 0.52–0.70).
Alexios S. Antonopoulos, Theodoros Tsampras, Dimitrios Terentes‐Printzios, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +5 more
wiley   +1 more source